Medscape is available in 5 Language Editions – Choose your Edition here.


Pediatric Multiple Endocrine Neoplasia

  • Author: Alicia Diaz-Thomas, MD, MPH; Chief Editor: Stephen Kemp, MD, PhD  more...
Updated: Aug 22, 2014


First reported in 1963 by Wermer, multiple endocrine neoplasia (MEN) syndromes, found in pediatric and adult patients, consist of rare, autosomal dominant mutations in genes that regulate cell growth.[1] Current classification recognizes type 1 and type 2 MEN, with the latter being divided into the subcategories type 2A MEN (Sipple syndrome) and type 2B MEN. (See Etiology.)

Menin protein, produced by the MENIN gene, is a tumor suppressor. Loss of this protein allows tumors to arise. Alternatively, Ret protein, produced by the RET gene, a proto-oncogene, can be constitutively activated, causing abnormal cell proliferation. (See Pathophysiology, Etiology, and Workup.)[2, 3]

Type 1 MEN

Type 1 MEN is defined by hyperfunctioning tumors in the following:

  • All 4 parathyroid glands
  • Pancreatic islets - Eg, gastrinoma, insulinoma, glucagonoma, vasoactive intestinal peptide tumor (VIPoma), pancreatic polypeptide–producing tumor (PPoma)
  • Anterior pituitary - Eg, prolactinoma, somatotropinoma, corticotropinoma, nonfunctioning tumors

Other associated tumors include lipomas, angiofibromas, and those located in the adrenal gland cortex (rarely, in the adrenal medulla).

Type 2A MEN

Type 2A MEN is defined by medullary thyroid carcinoma (MTC), pheochromocytoma (about 50% of cases), and hyperparathyroidism caused by parathyroid gland hyperplasia (about 20% of cases). (See Pathophysiology, Presentation, Workup, and Treatment.)

However, familial MTC is also recognized. Familial MTC is hereditary MTC without other associated endocrinopathies, although adrenomedullary hyperplasia secondary to a germline RET mutation may still be present but undiagnosed.

Type 2B MEN

Type 2B MEN is defined by MTC and pheochromocytoma. Associated abnormalities include mucosal neuromas, medullated corneal nerve fibers, and marfanoid habitus. (See Pathophysiology, Presentation, Workup, and Treatment.)


The prevalence of MEN in adults is about 0.02-0.2 cases per 1000 population in the United States. Data for children are not available.

The male-to-female ratio for MEN is 2:1. Patients with hyperparathy roidism in type 1 MEN most often present at age 20-40 years, but the disease may appear in children younger than 10 years. However, all MEN syndromes are rare in children.

Patient education

For patient education information, s ee Anatomy of the Endocrine System.

Families can locate an endocrinologist and access helpful information through the Hormone Foundation and the Endocrine and Metabolic Diseases Information Service, which is a service of the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health.



Type 1 MEN

Hyperparathyroidism is the most common manifestation of type 1 MEN (80% of presentations); it results from hyperplasia of all 4 parathyroid glands. Abnormalities of parathyroid hormone (PTH) secretion may affect children younger than 10 years.

Islet-cell tumors that secrete predominantly gastrin are called gastrinomas; these tumors frequently metastasize. Children rarely have gastrinomas. Pituitary tumors (eg, as prolactinoma) can affect children as young as 5 years. Adrenal involvement includes silent adenomas, adrenocortical hyperplasia, cortisol-secreting adenomas, and, rarely, carcinomas.

In addition, pheochromocytomas have been reported in patients with type 1 MEN. Thymic and bronchial carcinoid tumors can also be associated with type 1 MEN.[4] Lipomas and angiofibromas may often lead to the diagnosis of type 1 MEN before the endocrine manifestations.

Type 2A MEN (Sipple syndrome)

Type 2A MEN accounts for most cases of type 2 MEN. In general, type 2 MEN affects about 1 in 40,000 individuals, and fewer than 1000 kindreds are known worldwide. C-cell hyperplasia develops early in life and can be viewed as the precursor lesion for MTC, which often arises multifocally and bilaterally.

Pheochromocytomas are bilateral in 70% of cases and develop on the background of adrenomedullary hyperplasia secondary to an RET germline mutation. Biochemical manifestations, imaging manifestations, or both occur in about 50% of patients. The peak age at onset is approximately 40 years, but children as young as 10 years are reported.

Less than 25% of patients with type 2A MEN develop frank hyperparathyroidism; this condition is rare in childhood. Reasons for this low prevalence and discrepancy in type 2B MEN are unknown. Although various RET mutations can cause type 2B MEN, those mutations within exon 16 are most often reported in association with hyperparathyroidism.

Type 2B MEN

Type 2B MEN represents about 5% of all cases of type 2 MEN. Patients have some aspects of a distinctive marfanoid phenotype and mucosal neuromas. MTC is relatively aggressive and frequently occurs in childhood; children as young as 12 months may develop MTC. Therefore, prophylactic thyroidectomy with lymph node dissection is recommended in children younger than 5 years who have a RET germline mutation in exon 16.

Pheochromocytomas also occur earlier than in patients with type 2A MEN, and patients have the same features arising in the context of adrenomedullary hyperplasia, multifocality, and, often, bilateral involvement. In contrast to MTC, which frequently metastasizes, metastatic pheochromocytomas rarely occur in patients with type 2 MEN (0-25%). An important parameter in this setting is the follow-up period and the time of first occurrence or diagnosis.

Carney complex

Carney complex is a distinct, rare type of MEN characterized by primary pigmented adrenocortical disease, pituitary adenoma, Sertoli-cell tumors, thyroid nodules, and additional nonendocrine features. The most commonly associated features are cardiac and skin myxomas, melanotic schwannomas, and lentigines.



Type 1 MEN

The MENIN gene responsible for type 1 MEN has been localized to chromosome band 11q13; it produces a nuclear protein called menin, a tumor suppressor. The MENIN gene is ubiquitously expressed and is localized to the nucleus of cells; there is increasing evidence that menin may act in DNA repair or synthesis.

Patients with type 1 MEN possess a germline mutation in the MENIN gene and develop tumors when inactivation of the wild-type allele occurs, resulting in unsuppressed growth. Mutations are distributed over the entire coding region without showing any significant hot spot region.[5]

In type 1 MEN, neuroendocrine tumors can derive from various tissues, including the so-called APUD cells, as well as from pluripotent stem cells of these respective tissue (eg, pituitary tissue).[6] Most tumors arise in the pituitary gland and pancreatic islet cells. There is a lower incidence of parathyroid involvement in type 1 MEN compared with tumor rates in other tissues. However, patients with type 1 MEN–associated hyperparathyroidism tend to be younger than patients with sporadic primary hyperparathyroidism.

Type 2 MEN

The genetic mutation in type 2 MEN occurs in a proto-oncogene called RET, located on band 10q11.2. RET encodes the tyrosine kinase RET protein subunit of a cell surface receptor. Activation of RET leads to hyperplasia of target cells in vivo. Subsequent secondary events then lead to tumor formation. RET is specifically expressed in neural crest–derived cells, such as the C cells in the thyroid gland and the chromaffin cells in the adrenal gland. The presence or absence of RET expression in parathyroid tissue is unknown.

There are typical genetic signatures for most cases of type 2 MEN. In type 2A MEN, 95% of RET mutations occur in exons 10, 11, and 14. Of patients with type 2B MEN, 95% have a point mutation in exon 16 (M918T). A second point mutation at codon 883 has been found in 2-3% of type 2B MEN cases. Interestingly, risk stratification strategies, targeting the age of development of medullary thyroid cancer, have been developed. These are based on the genomic signature of the RET mutation. Consensus guidelines for children with the highest risk mutations (eg, c.918,c.883) recommend total thyroidectomy and central lymph node dissection as early as 6 months after birth.[7] Mechanisms of tumorigenesis that have been elucidated show allelic imbalance between mutant and wild type RET alleles.

Most cases of MTC and/or pheochromocytoma are sporadic. Only about 10% of cases are hereditary and related to type 2 MEN.

So-called inactivating mutations due to deletions of RET are associated with congenital neurologic defects, such as aganglionic colon (ie, Hirschsprung disease).[8] Of interest, these mutations also occur on exons 10 and 11 (associated with type 2A MEN).



Type 1 MEN

The prognosis is generally good in the presence of discrete parathyroid and pancreatic islet disease or pituitary adenoma. Pancreatic islet cell carcinoma and carcinoids are slowly progressive.

Patients with gastrinoma in type 1 MEN may have a prognosis better than that of patients with the sporadic form of the disease.

Type 2A MEN

The prognosis depends on the stage of medullary thyroid cancer and is generally good after prophylactic thyroidectomy.

Type 2B MEN

The prognosis for patients with type 2B MEN is worse than for patients with type 2A MEN because tumors, such as MTCs, are relatively aggressive, resulting in a 10-year survival rate of 50%.

Therefore, individuals with an RET germline mutation in exon 16 should undergo early prophylactic thyroidectomy and screening for pheochromocytomas. MTC may appear within the first year of life.

Morbidity and mortality

Death related to MEN can be caused by the following:

  • Complicated peptic ulcer disease
  • Metastases of endocrine pancreatic tumors
  • Severe hypercalcemia with arrhythmias
  • Metastatic MTC
  • Catecholamine release–related arrhythmias
  • Coronary heart disease
  • Stroke
  • Heart failure
  • Arrhythmias from cardiac myxomas

Zollinger-Ellison syndrome (ZES) is the major cause of morbidity and mortality in type 1 MEN. Mortality in type 2B MEN is mainly due to the aggressive nature of MTCs.

In a report on 103 patients with type 1 MEN, Doherty et al found that 46% of these individuals died from causes related to their endocrine tumors after a median of 47 years.[9]

Contributor Information and Disclosures

Alicia Diaz-Thomas, MD, MPH Assistant Professor of Pediatrics, University of Tennessee Health Science Center

Alicia Diaz-Thomas, MD, MPH is a member of the following medical societies: American Association of Clinical Endocrinologists, Endocrine Society, Pediatric Endocrine Society, Tennessee Medical Association

Disclosure: Nothing to disclose.

Chief Editor

Stephen Kemp, MD, PhD Former Professor, Department of Pediatrics, Section of Pediatric Endocrinology, University of Arkansas for Medical Sciences College of Medicine, Arkansas Children's Hospital

Stephen Kemp, MD, PhD is a member of the following medical societies: American Academy of Pediatrics, American Association of Clinical Endocrinologists, American Pediatric Society, Endocrine Society, Phi Beta Kappa, Southern Medical Association, Southern Society for Pediatric Research

Disclosure: Nothing to disclose.


George P Chrousos, MD, FAAP, MACP, MACE, FRCP (London) Professor and Chair, First Department of Pediatrics, Athens University Medical School, Aghia Sophia Children's Hospital, Greece; UNESCO Chair on Adolescent Health Care, University of Athens, Athens, Greece

George P Chrousos, MD, FAAP, MACP, MACE, FRCP(London) is a member of the following medical societies: American Academy of Pediatrics, American College of Endocrinology, American College of Physicians, American Pediatric Society, American Society for Clinical Investigation, Association of American Physicians, Endocrine Society, Lawson-Wilkins Pediatric Endocrine Society, and Society for Pediatric Research

Disclosure: Nothing to disclose.

Robert J Ferry Jr, MD Le Bonheur Chair of Excellence in Endocrinology, Professor and Chief, Division of Pediatric Endocrinology and Metabolism, Department of Pediatrics, University of Tennessee Health Science Center

Robert J Ferry Jr, MD is a member of the following medical societies: American Academy of Pediatrics, American Diabetes Association, American Medical Association, Endocrine Society, Pediatric Endocrine Society, Society for Pediatric Research, and Texas Pediatric Society

Disclosure: Eli Lilly & Co Grant/research funds Investigator; MacroGenics, Inc Grant/research funds Investigator; Ipsen, SA (formerly Tercica, Inc) Grant/research funds Investigator; NovoNordisk SA Grant/research funds Investigator; Diamyd Grant/research funds Investigator; Bristol-Myers-Squibb Grant/research funds Other; Amylin Other; Pfizer Grant/research funds Other; Takeda Grant/research funds Other

Christian A Koch, MD, PhD, FACP, FACE Professor and Director, Division of Endocrinology, University of Mississippi Medical Center

Christian A Koch, MD, PhD, FACP, FACE is a member of the following medical societies: American Academy of Neurology, American Association of Clinical Endocrinologists, American College of Clinical Endocrinologists, American College of Physicians-American Society of Internal Medicine, American Society for Clinical Pharmacology and Therapeutics, American Society for Dermatologic Surgery, Endocrine Society, and German Diabetes Society

Disclosure: NovoNordisk Honoraria Consulting

Lynne Lipton Levitsky, MD Chief, Pediatric Endocrine Unit, Massachusetts General Hospital; Associate Professor of Pediatrics, Harvard Medical School

Lynne Lipton Levitsky, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Pediatrics, American Diabetes Association, American Pediatric Society, Endocrine Society, Lawson-Wilkins Pediatric Endocrine Society, and Society for Pediatric Research

Disclosure: Pfizer Grant/research funds P.I.; Tercica Grant/research funds Other; Eli Lily Grant/research funds PI; NovoNordisk Grant/research funds PI

Klaus Radebold, MD, PhD Research Associate, Department of Surgery, Yale University School of Medicine

Klaus Radebold, MD, PhD is a member of the following medical societies: American Gastroenterological Association and New York Academy of Sciences

Disclosure: Nothing to disclose.

Arlan L Rosenbloom, MD Adjunct Distinguished Service Professor Emeritus of Pediatrics, University of Florida; Fellow of the American Academy of Pediatrics; Fellow of the American College of Epidemiology

Arlan L Rosenbloom, MD is a member of the following medical societies: American Academy of Pediatrics, American College of Epidemiology, American Pediatric Society, Endocrine Society, Florida Pediatric Society, Lawson-Wilkins Pediatric Endocrine Society, and Society for Pediatric Research

Disclosure: Nothing to disclose.

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

  1. Wermer P. Endocrine adenomatosis and peptic ulcer in a large kindred. Inherited multiple tumors and mosaic pleiotropism in man. Am J Med. 1963 Aug. 35:205-12. [Medline].

  2. Eng C. RET proto-oncogene in the development of human cancer. J Clin Oncol. 1999 Jan. 17(1):380-93. [Medline].

  3. Agarwal SK, Kennedy PA, Scacheri PC, Novotny EA, Hickman AB, Cerrato A, et al. Menin molecular interactions: insights into normal functions and tumorigenesis. Horm Metab Res. 2005 Jun. 37(6):369-74. [Medline].

  4. Lim LC, Tan MH, Eng C, Teh BT, Rajasoorya RC. Thymic carcinoid in multiple endocrine neoplasia 1: genotype-phenotype correlation and prevention. J Intern Med. 2006 Apr. 259(4):428-32. [Medline].

  5. Agarwal SK, Kester MB, Debelenko LV, et al. Germline mutations of the MEN1 gene in familial multiple endocrine neoplasia type 1 and related states. Hum Mol Genet. 1997 Jul. 6(7):1169-75. [Medline].

  6. Trouillas J, Labat-Moleur F, Sturm N, Kujas M, Heymann MF, Figarella-Branger D, et al. Pituitary tumors and hyperplasia in multiple endocrine neoplasia type 1 syndrome (MEN1): a case-control study in a series of 77 patients versus 2509 non-MEN1 patients. Am J Surg Pathol. 2008 Apr. 32(4):534-43. [Medline].

  7. Kloos RT, Eng C, Evans DB, et al. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid. 2009 Jun. 19(6):565-612. [Medline].

  8. Decker RA, Peacock ML. Occurrence of MEN 2a in familial Hirschsprung's disease: a new indication for genetic testing of the RET proto-oncogene. J Pediatr Surg. 1998 Feb. 33(2):207-14. [Medline].

  9. Doherty GM, Olson JA, Frisella MM, Lairmore TC, Wells SA Jr, Norton JA. Lethality of multiple endocrine neoplasia type I. World J Surg. 1998 Jun. 22(6):581-6; discussion 586-7. [Medline].

  10. Brandi ML, Gagel RF, Angeli A, et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab. 2001 Dec. 86(12):5658-71. [Medline].

  11. Thomas-Marques L, Murat A, Delemer B, Penfornis A, Cardot-Bauters C, Baudin E, et al. Prospective endoscopic ultrasonographic evaluation of the frequency of nonfunctioning pancreaticoduodenal endocrine tumors in patients with multiple endocrine neoplasia type 1. Am J Gastroenterol. 2006 Feb. 101(2):266-73. [Medline].

  12. Triponez F, Dosseh D, Goudet P, Cougard P, Bauters C, Murat A. Epidemiology data on 108 MEN 1 patients from the GTE with isolated nonfunctioning tumors of the pancreas. Ann Surg. 2006 Feb. 243(2):265-72. [Medline].

  13. Anlauf M, Schlenger R, Perren A, Bauersfeld J, Koch CA, Dralle H, et al. Microadenomatosis of the endocrine pancreas in patients with and without the multiple endocrine neoplasia type 1 syndrome. Am J Surg Pathol. 2006 May. 30(5):560-74. [Medline].

  14. Agarwal SK, Lee Burns A, Sukhodolets KE, Kennedy PA, Obungu VH, Hickman AB, et al. Molecular pathology of the MEN1 gene. Ann N Y Acad Sci. 2004 Apr. 1014:189-98. [Medline].

  15. Bahlo M, Schott M, Kaminsky E, Cupisti K. [Multiple endocrine neoplasia 2a: late manifestation of a newly-discovered mutation]. Dtsch Med Wochenschr. 2008 Mar. 133(10):464-6. [Medline].

  16. Berna MJ, Annibale B, Marignani M, Luong TV, Corleto V, Pace A, et al. A prospective study of gastric carcinoids and enterochromaffin-like cell changes in multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome: identification of risk factors. J Clin Endocrinol Metab. 2008 May. 93(5):1582-91. [Medline].

  17. Brauer VF, Scholz GH, Neumann S, Lohmann T, Paschke R, Koch CA. RET germline mutation in codon 791 in a family representing 3 generations from age 5 to age 70 years: should thyroidectomy be performed?. Endocr Pract. 2004 Jan-Feb. 10(1):5-9. [Medline].

  18. Byard RW, Thorner PS, Chan HS, Griffiths AM, Cutz E. Pathological features of multiple endocrine neoplasia type IIb in childhood. Pediatr Pathol. 1990. 10(4):581-92. [Medline].

  19. Carney JA, Gordon H, Carpenter PC, Shenoy BV, Go VL. The complex of myxomas, spotty pigmentation, and endocrine overactivity. Medicine (Baltimore). 1985 Jul. 64(4):270-83. [Medline].

  20. Ciccarelli A, Daly AF, Beckers A. The epidemiology of prolactinomas. Pituitary. 2005. 8(1):3-6. [Medline].

  21. Cohen MS, Phay JE, Albinson C, DeBenedetti MK, Skinner MA, Lairmore TC, et al. Gastrointestinal manifestations of multiple endocrine neoplasia type 2. Ann Surg. 2002 May. 235(5):648-54; discussion 654-5. [Medline].

  22. Craven DE, Goodman D, Carter JH. Familial multiple endocrine adenomatosis. Multiple endocrine neoplasia, type I. Arch Intern Med. 1972 Apr. 129(4):567-9. [Medline].

  23. Eriksson B, Bergstrom M, Orlefors H, Sundin A, Oberg K, Langstrom B. Use of PET in neuroendocrine tumors. In vivo applications and in vitro studies. Q J Nucl Med. 2000 Mar. 44(1):68-76. [Medline].

  24. Eriksson B, Oberg K, Stridsberg M. Tumor markers in neuroendocrine tumors. Digestion. 2000. 62 Suppl 1:33-8. [Medline].

  25. Ferry RJ Jr, Kelly A, Grimberg A, Koo-McCoy S, Shapiro MJ, Fellows KE, et al. Calcium-stimulated insulin secretion in diffuse and focal forms of congenital hyperinsulinism. J Pediatr. 2000 Aug. 137(2):239-46. [Medline].

  26. Frank K, Raue F, Gottswinter J, Heinrich U, Meybier H, Ziegler R. Importance of early diagnosis and follow-up in multiple endocrine neoplasia (MEN II B). Eur J Pediatr. 1984 Dec. 143(2):112-6. [Medline].

  27. Frohnauer MK, Decker RA. Update on the MEN 2A c804 RET mutation: is prophylactic thyroidectomy indicated?. Surgery. 2000 Dec. 128(6):1052-7;discussion 1057-8. [Medline].

  28. Garbrecht N, Anlauf M, Schmitt A, Henopp T, Sipos B, Raffel A, et al. Somatostatin-producing neuroendocrine tumors of the duodenum and pancreas: incidence, types, biological behavior, association with inherited syndromes, and functional activity. Endocr Relat Cancer. 2008 Mar. 15(1):229-41. [Medline].

  29. Georgitsi M, Raitila A, Karhu A, van der Luijt RB, Aalfs CM, Sane T, et al. Germline CDKN1B/p27Kip1 mutation in multiple endocrine neoplasia. J Clin Endocrinol Metab. 2007 Aug. 92(8):3321-5. [Medline].

  30. Granberg D, Stridsberg M, Seensalu R, Eriksson B, Lundqvist G, Oberg K, et al. Plasma chromogranin A in patients with multiple endocrine neoplasia type 1. J Clin Endocrinol Metab. 1999 Aug. 84(8):2712-7. [Medline].

  31. Grant F. Anesthetic considerations in the multiple endocrine neoplasia syndromes. Curr Opin Anaesthesiol. 2005 Jun. 18(3):345-52. [Medline].

  32. Gujral TS, van Veelen W, Richardson DS, Myers SM, Meens JA, Acton DS, et al. A novel RET kinase-beta-catenin signaling pathway contributes to tumorigenesis in thyroid carcinoma. Cancer Res. 2008 Mar 1. 68(5):1338-46. [Medline].

  33. Harrison B. Endocrine surgical aspects of multiple endocrine neoplasia syndromes in children. Horm Res. 2007. 68 Suppl 5:105-6. [Medline].

  34. Hassett S, Costigan C, McDermott M, Fitzgerald RJ. Prophylactic thyroidectomy in the treatment of thyroid medullary carcinoma. Age for surgery?. Eur J Pediatr Surg. 2000 Oct. 10(5):334-6. [Medline].

  35. Huang SC, Koch CA, Vortmeyer AO, Pack SD, Lichtenauer UD, Mannan P, et al. Duplication of the mutant RET allele in trisomy 10 or loss of the wild-type allele in multiple endocrine neoplasia type 2-associated pheochromocytomas. Cancer Res. 2000 Nov 15. 60(22):6223-6. [Medline].

  36. Iler MA, King DR, Ginn-Pease ME, O'Dorisio TM, Sotos JF. Multiple endocrine neoplasia type 2A: a 25-year review. J Pediatr Surg. 1999 Jan. 34(1):92-6; discussion 96-7. [Medline].

  37. Imai Y, Fukase M, Tsutsumi M, Fukami T, Sakaguchi K, Furumoto M, et al. A case of multiple endocrine neoplasia type II b: endocrinological evaluation and family screening. Endocrinol Jpn. 1982 Feb. 29(1):49-56. [Medline].

  38. Johnston LB, Chew SL, Trainer PJ, Reznek R, Grossman AB, Besser GM, et al. Screening children at risk of developing inherited endocrine neoplasia syndromes. Clin Endocrinol (Oxf). 2000 Feb. 52(2):127-36. [Medline].

  39. Kameya T, Tsukada T, Yamaguchi K. Recent advances in MEN1 gene study for pituitary tumor pathogenesis. Front Horm Res. 2004. 32:265-91. [Medline].

  40. Koch CA. Molecular pathogenesis of MEN2-associated tumors. Fam Cancer. 2005. 4(1):3-7. [Medline].

  41. Koch CA, Pacak K, Chrousos GP. Endocrine tumors. Pizzo PA, Poplack DG, eds. Principles and Practice of Pediatric Oncology. 5th ed. Philadelphia, Pa: Lippincott Raven; 2006.

  42. Koch CA, Pacak K, Chrousos GP. The molecular pathogenesis of hereditary and sporadic adrenocortical and adrenomedullary tumors. J Clin Endocrinol Metab. 2002 Dec. 87(12):5367-84. [Medline].

  43. Lowney JK, Frisella MM, Lairmore TC, Doherty GM. Pancreatic islet cell tumor metastasis in multiple endocrine neoplasia type 1: correlation with primary tumor size. Surgery. 1998 Dec. 124(6):1043-8, discussion 1048-9. [Medline].

  44. Mailman MD, Muscarella P, Schirmer WJ, Ellison EC, O'Dorisio TM, Prior TW. Identification of MEN1 mutations in sporadic enteropancreatic neuroendocrine tumors by analysis of paraffin-embedded tissue. Clin Chem. 1999 Jan. 45(1):29-34. [Medline].

  45. Marx S, Spiegel AM, Skarulis MC, Doppman JL, Collins FS, Liotta LA. Multiple endocrine neoplasia type 1: clinical and genetic topics. Ann Intern Med. 1998 Sep 15. 129(6):484-94. [Medline].

  46. Marx SJ. Molecular genetics of multiple endocrine neoplasia types 1 and 2. Nat Rev Cancer. 2005 May. 5(5):367-75. [Medline].

  47. McCarthy PM, Piehler JM, Schaff HV, Pluth JR, Orszulak TA, Vidaillet HJ Jr, et al. The significance of multiple, recurrent, and "complex" cardiac myxomas. J Thorac Cardiovasc Surg. 1986 Mar. 91(3):389-96. [Medline].

  48. Miehle K, Kratzsch J, Lenders JW, Kluge R, Paschke R, Koch CA. Adrenal incidentaloma diagnosed as pheochromocytoma by plasma chromogranin A and plasma metanephrines. J Endocrinol Invest. 2005 Dec. 28(11):1040-2. [Medline].

  49. Neumann HP, Vortmeyer A, Schmidt D, Werner M, Erlic Z, Cascon A, et al. Evidence of MEN-2 in the original description of classic pheochromocytoma. N Engl J Med. 2007 Sep 27. 357(13):1311-5. [Medline].

  50. Norton JA, Fang TD, Jensen RT. Surgery for gastrinoma and insulinoma in multiple endocrine neoplasia type 1. J Natl Compr Canc Netw. 2006 Feb. 4(2):148-53. [Medline].

  51. O'Brien T, O'Riordan DS, Gharib H, Scheithauer BW, Ebersold MJ, van Heerden JA. Results of treatment of pituitary disease in multiple endocrine neoplasia, type I. Neurosurgery. 1996 Aug. 39(2):273-8; discussion 278-9. [Medline].

  52. Oberg K. Interferon in the management of neuroendocrine GEP-tumors: a review. Digestion. 2000. 62 Suppl 1:92-7. [Medline].

  53. Ogilvie JB, Kebebew E. Indication and timing of thyroid surgery for patients with hereditary medullary thyroid cancer syndromes. J Natl Compr Canc Netw. 2006 Feb. 4(2):139-47. [Medline].

  54. Pacak K, Chrousos GP, Koch CA, et al. Pheochromocytoma: progress in diagnosis, therapy, and genetics. Margioris A, Chrousos GP, eds. Adrenal Disorders. Humana Press: Totowa, NJ; 2001.

  55. Parlowsky T, Bucsky P, Hof M, Kaatsch P. Malignant endocrine tumours in childhood and adolescence--results of a retrospective analysis. Klin Padiatr. 1996 Jul-Aug. 208(4):205-9. [Medline].

  56. Proye CA, Nguyen HH. Current perspectives in the surgery of multiple endocrine neoplasias. Aust N Z J Surg. 1999 Feb. 69(2):106-16. [Medline].

  57. Pujol RM, Matias-Guiu X, Miralles J, Colomer A, de Moragas JM. Multiple idiopathic mucosal neuromas: a minor form of multiple endocrine neoplasia type 2B or a new entity?. J Am Acad Dermatol. 1997 Aug. 37(2 Pt 2):349-52. [Medline].

  58. Ruszniewski P, Podevin P, Cadiot G, Marmuse JP, Mignon M, Vissuzaine C, et al. Clinical, anatomical, and evolutive features of patients with the Zollinger-Ellison syndrome combined with type I multiple endocrine neoplasia. Pancreas. 1993 May. 8(3):295-304. [Medline].

  59. Sakurai A, Uchino S, Takami H. Current status of clinical care for familial endocrine tumor syndromes in Japan. Endocr J. 2005 Dec. 52(6):757-62. [Medline].

  60. Scacheri PC, Davis S, Odom DT, Crawford GE, Perkins S, Halawi MJ, et al. Genome-wide analysis of menin binding provides insights into MEN1 tumorigenesis. PLoS Genet. 2006 Apr. 2(4):e51. [Medline].

  61. Scarsbrook AF, Thakker RV, Wass JA, Gleeson FV, Phillips RR. Multiple endocrine neoplasia: spectrum of radiologic appearances and discussion of a multitechnique imaging approach. Radiographics. 2006 Mar-Apr. 26(2):433-51. [Medline].

  62. Shan L, Nakamura Y, Nakamura M, Yokoi T, Tsujimoto M, Arima R, et al. Somatic mutations of multiple endocrine neoplasia type 1 gene in the sporadic endocrine tumors. Lab Invest. 1998 Apr. 78(4):471-5. [Medline].

  63. Skinner MA, DeBenedetti MK, Moley JF, Norton JA, Wells SA Jr. Medullary thyroid carcinoma in children with multiple endocrine neoplasia types 2A and 2B. J Pediatr Surg. 1996 Jan. 31(1):177-81; discussion 181-2. [Medline].

  64. Skinner MA, Moley JA, Dilley WG, Owzar K, Debenedetti MK, Wells SA Jr. Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A. N Engl J Med. 2005 Sep 15. 353(11):1105-13. [Medline].

  65. Skinner MA, Wells SA Jr. Medullary carcinoma of the thyroid gland and the MEN 2 syndromes. Semin Pediatr Surg. 1997 Aug. 6(3):134-40. [Medline].

  66. Skogseid B, Doherty GM. Multiple endocrine neoplasia type 1: clinical and genetic features. Ital J Gastroenterol Hepatol. 1999 Oct. 31 Suppl 2:S131-4. [Medline].

  67. Stratakis CA. Genetics of Carney complex and related familial lentiginoses, and other multiple tumor syndromes. Front Biosci. 2000 Mar 1. 5:D353-66. [Medline].

  68. Stratakis CA, Schussheim DH, Freedman SM, Keil MF, Pack SD, Agarwal SK, et al. Pituitary macroadenoma in a 5-year-old: an early expression of multiple endocrine neoplasia type 1. J Clin Endocrinol Metab. 2000 Dec. 85(12):4776-80. [Medline].

  69. Tagge EP, Hill JG, Tagge DU, Macpherson R. Pancreatic surgery in children. Curr Opin Pediatr. 1995 Jun. 7(3):342-8. [Medline].

  70. Thompson NW. Management of pancreatic endocrine tumors in patients with multiple endocrine neoplasia type 1. Surg Oncol Clin N Am. 1998 Oct. 7(4):881-91. [Medline].

  71. van Heurn LW, Schaap C, Sie G, Haagen AA, Gerver WJ, Freling G, et al. Predictive DNA testing for multiple endocrine neoplasia 2: a therapeutic challenge of prophylactic thyroidectomy in very young children. J Pediatr Surg. 1999 Apr. 34(4):568-71. [Medline].

  72. Vasen HF, Lamers CB, Lips CJ. Screening for the multiple endocrine neoplasia syndrome type I. A study of 11 kindreds in The Netherlands. Arch Intern Med. 1989 Dec. 149(12):2717-22. [Medline].

  73. Wang EH, Ebrahimi SA, Wu AY, Kashefi C, Passaro E Jr, Sawicki MP. Mutation of the MENIN gene in sporadic pancreatic endocrine tumors. Cancer Res. 1998 Oct 1. 58(19):4417-20. [Medline].

  74. Whelan T, Gatfield CT, Robertson S, Carpenter B, Schillinger JF. Primary carcinoid of the prostate in conjunction with multiple endocrine neoplasia IIb in a child. J Urol. 1995 Mar. 153(3 Pt 2):1080-2. [Medline].

  75. Zollinger RM, Ellison EH. Primary peptic ulcerations of the jejunum associated with islet cell tumors of the pancreas. Ann Surg. 1955 Oct. 142(4):709-23; discussion, 724-8. [Medline].

  76. Dreijerink KM, Goudet P, Burgess JR, Valk GD,. Breast-cancer predisposition in multiple endocrine neoplasia type 1. N Engl J Med. 2014 Aug 7. 371(6):583-4. [Medline].

  77. Thakker RV, Newey PJ, Walls GV, et al. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab. 2012 Sep. 97(9):2990-3011. [Medline].

  78. Castinetti F, Qi XP, Walz MK, Maia AL, Sansó G, Peczkowska M. Outcomes of adrenal-sparing surgery or total adrenalectomy in phaeochromocytoma associated with multiple endocrine neoplasia type 2: an international retrospective population-based study. Lancet Oncol. 2014 May. 15(6):648-55. [Medline].

All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.